hepatitis

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. The drug has been accepted for the treatment of chronic HDV infection in adult patients with evidence of significant fibrosis, whose disease has […]

Biopharmaceutical company VBI Vaccines has revealed interim data from its Phase II study evaluating the combination of VBI-2601, VBI’s HBV immunotherapeutic candidate, and BRII-835, an HBV-targeting siRNA candidate, in chronically infected hepatitis B (HBV) patients.   The data demonstrate that the combination therapy was generally well-tolerated, restored strong anti-HBsAg antibody responses, and led to improved HBsAg-specific […]